nanoSyrinx

NanoSyrinx is a discovery stage biotechnology company developing new therapeutic modalities for Cell & Gene editing. This is the first company to engineer ‘nanosyringes’, a selective non-viral peptide and protein delivery system identified in an undisclosed organism. NanoSyrinx is developing a fully customisable genetic platform that selectively delivers peptide and protein payloads – including functional gene editing enzymes and nucleases – directly to the cytosol of targeted cells. NanoSyrinx is based at the University of Warwick’s Medical School.